Mild headache, dizziness, or fatigue
This review also addressed the compounds patent landscape and emerging research directions, providing the most authoritative single-source overview of BPC-157 science available as of early 2026 (Jozwiak et al., 2025, Pharmaceuticals (Basel)
Patients may notice reduced fatigue and improved wellbeing within two to four weeks, whilst macrocytic anaemia typically resolves over six to eight weeks
The term apheresis, often used to describe TPE, came from that experiment
Shots can be taken bi-monthly or monthly
About ARA-290 ARA-290 (also known as Cibinetide) is a synthetic peptide derived from the helical region of erythropoietin (EPO) that is specifically engineered to interact with the innate-repair receptor (IRR) rather than the classical EPO receptor